Capricor Therapeutics, Inc.
CAPR
Price:
$4.4
Market Cap:
$143.17M
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, whic...[Read more]
Industry
Biotechnology
IPO Date
2007-02-13
Stock Exchange
NASDAQ
Ticker
CAPR
The ROE as of September 2024 (TTM) for Capricor Therapeutics, Inc. (CAPR) is -220.26%
According to Capricor Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -220.26%. This represents a change of -529.04% compared to the average of 51.34% of the last 4 quarters.
Capricor Therapeutics, Inc. (CAPR) Historical ROE (quarterly & annually)
How has CAPR ROE performed in the past?
The mean historical ROE of Capricor Therapeutics, Inc. over the last ten years is 94.56%. The current -220.26% ROE has changed -332.94% with respect to the historical average. Over the past ten years (40 quarters), CAPR's ROE was at its highest in in the March 2023 quarter at 6.58%. The ROE was at its lowest in in the September 2016 quarter at -10855.49%.
Average
94.56%
Median
-54.84%
Minimum
-329.13%
Maximum
1.25%
Capricor Therapeutics, Inc. (CAPR) ROE by Quarter and Year
Discovering the peaks and valleys of Capricor Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.15%
Maximum Annual ROE = 1.25%
Minimum Annual Increase = -1619.71%
Minimum Annual ROE = -329.13%
| Year | ROE | Change |
|---|---|---|
| 2023 | -98.61% | -59.95% |
| 2022 | -246.21% | 297.92% |
| 2021 | -61.88% | 29.44% |
| 2020 | -47.80% | -55.69% |
| 2019 | -107.87% | -67.22% |
| 2018 | -329.13% | -1619.71% |
| 2017 | 21.66% | -95.39% |
| 2016 | 469.80% | -62.30% |
| 2015 | 1.25% | 1.15% |
| 2014 | 99.49% | -94.02% |
Capricor Therapeutics, Inc. (CAPR) Average ROE
How has CAPR ROE performed in the past?
The current ROE of Capricor Therapeutics, Inc. (CAPR) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-135.57%
5-year avg
-112.47%
10-year avg
94.56%
Capricor Therapeutics, Inc. (CAPR) ROE vs. Peers
How is CAPR’s ROE compared to its peers?
Capricor Therapeutics, Inc.’s ROE is greater than Bio-Path Holdings, Inc. (-2842.40%), less than Catalyst Biosciences, Inc. (1.20%), greater than Diffusion Pharmaceuticals Inc. (-55460.19%), greater than NextCure, Inc. (-57.63%), greater than Pulmatrix, Inc. (-61.78%), less than Akari Therapeutics, Plc (1.04%), greater than Soleno Therapeutics, Inc. (-43.25%), less than Unicycive Therapeutics, Inc. (294.74%), greater than Cidara Therapeutics, Inc. (-401.89%), greater than Phio Pharmaceuticals Corp. (-142.68%), greater than Onconova Therapeutics, Inc. (-144.95%), greater than Moleculin Biotech, Inc. (-100.16%), greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%),
| Company | ROE | Market cap |
|---|---|---|
| -2842.40% | $2.65M | |
| 1.20% | $19.42M | |
| -55460.19% | $8.98M | |
| -57.63% | $36.09M | |
| -61.78% | $7.45M | |
| 1.04% | $41.66M | |
| -43.25% | $2.05B | |
| 294.74% | $35.49M | |
| -401.89% | $81.36M | |
| -142.68% | $2.80M | |
| -144.95% | $20.90M | |
| -100.16% | $6.74M | |
| -20.53% | $3.15B | |
| -255.67% | $1.17B | |
| -86.28% | $325.85M | |
| -44.73% | $2.10B | |
| -100.91% | $3.02M |
Build a custom stock screener for Capricor Therapeutics, Inc. (CAPR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Capricor Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Capricor Therapeutics, Inc. (CAPR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Capricor Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Capricor Therapeutics, Inc.'s ROE?
How is the ROE calculated for Capricor Therapeutics, Inc. (CAPR)?
What is the highest ROE for Capricor Therapeutics, Inc. (CAPR)?
What is the 3-year average ROE for Capricor Therapeutics, Inc. (CAPR)?
What is the 5-year average ROE for Capricor Therapeutics, Inc. (CAPR)?
How does the current ROE for Capricor Therapeutics, Inc. (CAPR) compare to its historical average?